Bill Hinshaw, Axcella CEO

Ax­cel­la touts in­ter­im NASH da­ta but needs cash to stay afloat for 2024 topline read­out

Ax­cel­la Ther­a­peu­tics, with an emp­ty bank ac­count loom­ing in the first quar­ter of next year and a re­cent set­back in a mid-stage long Covid study, is out with some in­ter­im da­ta on its NASH drug.

The biotech isn’t yet say­ing how the drug per­formed on the pri­ma­ry end­point of im­prove­ment in the non­al­co­holic fat­ty liv­er dis­ease (NAFLD) Ac­tiv­i­ty Score (NAS), but the first batch of re­sults has sent shares $AXLA soar­ing near­ly 15% be­fore Thurs­day’s open­ing bell.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.